The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $483,075 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to New York University (NYU) School of Medicine. The 2-year grant, effective June 13, 2024, will support research to determine whether the increased levels of the oxidative enzyme xanthine oxidase (XO) in malaria patients contribute to the development of severe malarial anemia. The project aims to study the mechanisms by which XO may induce hemolysis and/or phagocytosis of uninfected red blood cells, both in vitro using human cells and in a mouse model of malaria infection. Validating XO as a key contributor to malaria-induced anemia could lead to the development of new adjunctive therapies. The project leverages NYU's expertise in biomedical and clinical research on infectious diseases and related conditions.
Generated 3/4/25, 4:42 AM